Journals / Haydarpaşa Numune Eğitim ve Araştırma Hastanesi Tıp Dergisi / 2007 / Cilt: 47 - Sayı: 2

Diagnostic value of serum Ca 125 in pelvic mass; malign or benign

Pelvik kitlelerde malign-benign ayırımında serum CA 125 düzeyinin tanısal değeri

Pages
295–299
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: It is concluded that the serum CA 125 levels were found as useful criteria for the differentiation of malign and benign, in particular, in postmenoposal period but it is not sufficient as a sole diagnostic approach.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: In this study, the effects of high serum CA 125 levels for the differentiation of malign and benign were investigated in patients with pelvic mass.
📊
Key Findings & Data:Material-Method: A total of 111 patients undergone operation due to pelvic tumour in Obstetric and Gynaecology Clinic in Faculty of Medicine in University of Dicle, Turkey were retrospectively studied.
💡
Conclusion & Impact:Conclusion: It is concluded that the serum CA 125 levels were found as useful criteria for the differentiation of malign and benign, in particular, in postmenoposal period but it is not sufficient as a sole diagnostic approach.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: In this study, the effects of high serum CA 125 levels for the differentiation of malign and benign were investigated in patients with pelvic mass. Material-Method: A total of 111 patients undergone operation due to pelvic tumour in Obstetric and Gynaecology Clinic in Faculty of Medicine in University of Dicle, Turkey were retrospectively studied. The serum CA 125 levels of the patients were also included in the reports. The patients were divided into three groups according to histopathological findings as Group 1; benign, group 2; malign, group 3; borderline. The serum CA 125 values determined in the malign and benign cases were compared among groups. Statistical analysis were performed using X2 and Student t test.Results: The number of patients were assigned as Group 1; benign (n=64), Group 2; malign (n=45), Group 3 and borderline (n=2). High levels of serum CA 125 were determined in 29% (n=19) and 60% (n=27) of the patients in Group 1 and Group 2, respectively. The difference was statistically significant (p0.05). Sensitivity, specificity, positive and negative predictive value were determined 60%, 70%, 58% and 71% in patient with pre-postmenoposal status, 50%, 68%, 43% and 74% in patient with premenoposal status, 73%, 80%, 87% ve 61 % in patient with postmenoposal status, respectively. Conclusion: It is concluded that the serum CA 125 levels were found as useful criteria for the differentiation of malign and benign, in particular, in postmenoposal period but it is not sufficient as a sole diagnostic approach.

Özet

Pelvik kitle tespit edilen hastalarda malign-benign ayrımının yapılabilmesinde yüksek Serum CA 125 düzeylerinin etkinliğini belirlemek amaçlandı. Materyal-Metod: Dicle Üniversitesi Tıp Fakültesi Kadın Hastalıkları ve Doğum Kliniğinde pelvik kitle nedeniyle öpere edilmiş ve Serum CA 125 düzeyleri çalışılmış toplam 111 hasta retrospektif olarak incelendi. Serum CA 125 düzeyi için cut-off değeri 35 İÜ/mi olarak kabul edildi. Hastalar histopatolojik tanılarına göre Grup 1; benign, Grup 2; malign, Grup 3; borderline olarak 3 gruba ayrıldı. Malign ve benign olgulardaki tespit edilmiş Serum CA 125 değerleri gruplar arasında karşılaştırıldı. İstatistiksel analizler için X2 ve Student t testi kullanıldı. Bulgular: Grup 1; benign (n=64), Grup 2; malign (n=45), Grup 3; borderline (n=2) tespit edildi. Grup 1 'de %29 (n=19), Grup 2'de %60 (n=27) hastada yüksek Serum CA 125 düzeyleri tespit edildi ve aralarındaki fark istatistik olarak anlamlı bulundu (p0.05). Sensitivite, spesifisite, pozitif ve negatif belirleyicilik sırasıyla menopozal durumdan bağımsız; %60, %70, %58 ve %71, premenopozal dönemde; %50, %68, %43 ve %74, postmenopozal dönemde; %73, %80, İ&87 ve %61 tespit edildi. Sonuç: Serum CA 125'in pelvik kitlelerin malign-be-ning ayırımında postmenopozal dönemde daha fazla olmak üzere belirgin olarak faydalı, ancak tek başına yetersiz olduğu kanısına varıldı.

🔖

Cite This Article

KARACA, M., GÜL, T. (2022). Diagnostic value of serum Ca 125 in pelvic mass; malign or benign. Haydarpaşa Numune Eğitim ve Araştırma Hastanesi Tıp Dergisi, Cilt: 47 - Sayı: 2, 295–299. https://ajindex.com/articles/535596

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Van Nagell JR. Tumor markers in ovarian cancer. Clin in Obstet Gynaecol 1983
  2. Karaca M, Gocmen A, Sari A, Ugur MG. Effect of hystero-salpingography on serum cancer antigen (CA-125) levels. Eur J Gynaecol Oncol. 2005
  3. De Sa Rosa e Silva AC, Rosa e Silva JC, Nogueira AA, Pet-ta CA, Abrao MS, Ferriani RA. The levonorgestrel-releasing in-trauterine device reduces CA-125 serum levels in patients with endometriosis. Fertil Steril. 2006
  4. Panza N, Pacilio G, Campenella L, et al. Cancer antigen 125, tissue polypeptide antigen, Carcinoembryonik antigen, and beta chain human chorionicgonodotraphin as serum markers of epithelial ovarian carcinoma. Cancer 1988
  5. Fioretti P, Gadducci A, Ferdeghini M, Bortolini T. Corralati-on of CA 125 and CA 19.9 serum levels with clinical course and second look findings in patient with ovarian carcinoma. Gnaecol Oncol 1987
  6. McGuckin M.A, Layton G.T, Bailey M.C, Hurst T. Evaluation of two new assay for tumor associated antigens, CASA and OSA, found in the serum of patients with epithelial ovarian carcinoma-comparison with CA 125. Gynaecol Oncol 1990
  7. Mackay E.V, Khoo S.K, Daunter B. Tumor markers. Gynaecol Oncol. Ed. Malcolm Coppleson. 2nd edition, Vol 1, Hong Kong, Longman Group (EF) Ltd: 1992
  8. Dixia C, Schwartz R.E, Xingon L. etal: Multimodal approach to screening for ovarian cancer. Lancet I
  9. Vergote IB, Bormer OP, Abeler VM. Evaluation of serum CA 125 levels in the monitoring of ovarian cancer. Am J Obstet Gynecol 1987
  10. Chalas E, Welshinger M, Engellener W. The clinical significance of thrombocytosis in women presenting with pelvic mass. Am J Obstet Gynecol. 1992
  11. Önvural B, Laçin S, Saygılı U, Ulman C. Adneksiyal Kitleli Olgularda Preoperatif Trombosit ve Serum CA-125 Düzeylerinin Anlamı. Jinekoloji ve Obstetrik Dergisi. 1996
  12. Üstün C, Yanık F, Koçak İ, Uzel A, CanbazA, Çokşenim Ş: Adneksiyal kitlelerin preoperatif değerlendirilmesinde trombosit sayımı, CA 125 ve ultrasonografi. T Klin Jinekol Obst. 1997
  13. Schutter EM, Davelaar EM, van Kamp GJ, Verstraeten RA, Kenemans P, Verheijen RH. The differential diagnostic potential of a panel of tumor markers (CA 125, CA 15-3, and CA 72-4 antigens) in patients with a pelvic mass. Am J Obstet Gynecol. 2002
  14. Finkler NJ, Benecerraf B, Lavin P, et al: Comparison of serum CA 125, clinical impression and ultrasound in the preope-